Actavis sells USD 3 mln worth of Romania-produced oncology drugs on the US market

Pharmaceutical producer Actavis sold USD 3 million worth of oncology drugs produced by its subsidiary Sindan Pharma in its Romanian factory, according to the company. This was an increase of 50 percent compared to 2009. The company sold eight types of products on the US market and reached a sales volume of 152,000 units. The year before, Sindan Pharma had sold seven products on the US market, with a volume of 75,000 units worth USD 2 million in sales. Actavis Romania posted a turnover of EUR 93 million last year. The Bucharest – based factory exports products in over 53 countries. The Sindan factory has recently been reviewed by the US Food and Drug Administration (FDA) and the visit to Romania yielded positive results, according to Actavis. “The review, between March 28 and April 6, was triggered by the increase in the drugs produced by Sindan Pharma and sold on the US market, as well as by the higher number of authorization request submitted by the company in order to sell more products on the US market,” according to a company statement. Sindan Pharma is a Romanian company which produces oncology medicine, set up by Romanian businessman Dan Stoicescu. He sold the company to Icelandic drug producer Actavis in 2006, in a deal worth USD 177 million. editor@romania-insider.com